Zynerba Pharma: ZYN002 STAR 1 Trial Fails To Meet Primary Endpoint - Quick Facts

(RTTNews) - Zynerba Pharmaceuticals, Inc. (ZYNE) announced top-line results from its double-blind placebo controlled Phase 2 STAR 1 clinical trial evaluating ZYN002 in adult epilepsy patients with focal seizures. The company said, in the study, ZYN002 did not demonstrate a statistically significant reduction of focal seizures during the treatment period compared to the baseline period for either the high or low dose cohorts compared to placebo.

Armando Anido, CEO of Zynerba, said: "We are continuing to evaluate this study and the ongoing STAR 2 open label study to determine next steps with ZYN002 in adult epilepsy patients with focal seizures. The results demonstrated ZYN002 to have a very favorable safety and tolerability profile, which is an encouraging fact as we look to develop ZYN002 as a treatment for a wide range of indications."